Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6908-6915

  Hoekstra, Ronald ^a,e   Dumez, Herlinde ^b   Eskens, Ferry A L M ^a   Van Der Gaast, Ate ^a   Planting, Andre S T ^a   De Heus, Gerda ^a   Sizer, Kurt C ^d   Ravera, Christina ^c   Vaidyanathan, Sujata ^c   Bucana, Corazon ^d   Fidler, Isaiah J ^d   Van Oosterom, Allan T ^b   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CGP 75166; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CARCINOMA; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG TOLERABILITY; DRY SKIN; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FOLLICULITIS; FOOD DRUG INTERACTION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA; OVARY CARCINOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; TREATMENT OUTCOME; XEROSTOMIA;

ABSORPTION; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOFTWARE; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 26444610104     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0720     Document Type: Article

References (17)

1. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19:32-40s.
2. Pederson MW, Meltorn N, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anticancer therapy. Ann Oncol 2001;12:745-60.
3. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
4. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
5. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-25.
6. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
7. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trialist Group (NCIC CTG) trial [abstract]. Proc Am Soc Clin Oncol 2004;22:622s (7022).
8. PKI166, clinical research and development: investigators brochure. Edition 1.3. East Hanover (NJ): Novartis Pharmaceutical Corp. 16 March 2001.
9. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990;46:33-48.
10. Goodman S, Zahurak M, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14: 1149-61.
11. WHO. WHO handbook for reporting results of cancer treatment. WHO Offset Publ., No. 4. Geneva: WHO; 1979.
12. Description and validation of an analytical HPLC method for the determination of PKI166 in biological matrices. Drug metabolism and pharmacokinetics. Report DMPK (CH) R99-767. Basel (Switzerland): Novartis Pharma AG. 5 Feb. 1999.
13. Span PN, Grebenchtchikov N, Geurts-Moespot J, Westphal JR, Lucassen AMJ, Sweep CGJ. EORTC receptor and biomarker study group report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers 2000;15:184-91.
14. Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 2002;21:95a (377).
15. Dumez H, Hoekstra R, Eskens F, et al. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 2002;21:86a (341).
16. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
17. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59,